Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer

Summary

This study is being conducted to determine the effectiveness of standard 3 weekly treatments using docetaxel and prednisone with metformin in patients with castration-resistant metastatic prostate cancer. It is also being conducted to determine the levels of toxicity of metformin when added to every 3 weekly docetaxel treatments in patients with endocrine resistent, metastatic prostate cancer.

Timeline

Start

2011-06

Primary completion

2011-10

Completion

2011-10

Outcome

Outcome not reported

Stopped (Enrollment): “No accrual in initial period, PI decided to close study.”

Drugs

Indications